[{"id":"ef5ef83b-bc3d-4dc9-9b78-e271828de65e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06050122","created_at":"2023-09-22T14:10:44.436Z","updated_at":"2024-07-02T16:35:08.695Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","source_id_and_acronym":"NCT06050122","lead_sponsor":"Sol-Gel Technologies, Ltd.","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (SGT-610)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/17/2024","start_date":" 03/17/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-19"},{"id":"ffb94954-f1c1-4247-b33c-267b8f6f3014","acronym":"","url":"https://clinicaltrials.gov/study/NCT04231851","created_at":"2021-01-18T20:35:11.661Z","updated_at":"2024-07-02T16:35:20.841Z","phase":"Phase 2","brief_title":"CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia","source_id_and_acronym":"NCT04231851","lead_sponsor":"University of California, Irvine","biomarkers":" NPM1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation) • Daurismo (glasdegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/19/2020","start_date":" 02/19/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-02-05"},{"id":"7d881018-0265-4ecb-9d18-1c4241cf9170","acronym":"","url":"https://clinicaltrials.gov/study/NCT05199584","created_at":"2022-01-20T14:53:33.589Z","updated_at":"2024-07-02T16:35:26.000Z","phase":"Phase 2","brief_title":"A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations","source_id_and_acronym":"NCT05199584","lead_sponsor":"Endeavor Biomedicines, Inc.","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e taladegib (ENV 101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 05/24/2022","start_date":" 05/24/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-12-18"},{"id":"f514e125-fc12-410e-8afb-782e274842a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04655391","created_at":"2021-01-19T20:41:28.630Z","updated_at":"2024-07-02T16:36:09.137Z","phase":"Phase 1b","brief_title":"Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT04655391","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • ABL1 • BCR • IDH1 • AXL","pipe":" | ","alterations":" IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836","tags":["FLT3 • ABL1 • BCR • IDH1 • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • bosutinib • decitabine • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Daurismo (glasdegib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/25/2022","start_date":" 06/25/2022","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2022-06-09"},{"id":"d06e8af1-41a9-44ee-8b8e-7998ed004a25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03703310","created_at":"2021-01-18T18:08:53.199Z","updated_at":"2024-07-02T16:36:33.679Z","phase":"Phase 3","brief_title":"Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)","source_id_and_acronym":"NCT03703310","lead_sponsor":"PellePharm, Inc.","biomarkers":" PTCH1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (SGT-610)"],"overall_status":"Completed","enrollment":" Enrollment 174","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 12/28/2020","primary_completion_date":" 12/28/2020","study_txt":" Completion: 12/28/2020","study_completion_date":" 12/28/2020","last_update_posted":"2021-03-08"},{"id":"9d1cbdcb-bda6-4638-bfe0-b1a719e61280","acronym":"","url":"https://clinicaltrials.gov/study/NCT02762084","created_at":"2021-01-18T13:32:43.587Z","updated_at":"2024-07-02T16:36:42.846Z","phase":"Phase 2","brief_title":"Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients","source_id_and_acronym":"NCT02762084","lead_sponsor":"PellePharm, Inc.","biomarkers":" PTCH1 • GLI1","pipe":" | ","alterations":" PTCH1 mutation","tags":["PTCH1 • GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTCH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (SGT-610)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 06/06/2016","start_date":" 06/06/2016","primary_txt":" Primary completion: 04/24/2017","primary_completion_date":" 04/24/2017","study_txt":" Completion: 04/24/2017","study_completion_date":" 04/24/2017","last_update_posted":"2020-07-23"},{"id":"2c7078b6-9b43-4e89-b4ca-220ebb7b3987","acronym":"","url":"https://clinicaltrials.gov/study/NCT03734913","created_at":"2021-01-18T18:17:40.491Z","updated_at":"2024-07-02T16:36:42.875Z","phase":"Phase 1","brief_title":"A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT03734913","lead_sponsor":"Guangdong Zhongsheng Pharmaceutical Co., Ltd.","biomarkers":" GLI1","pipe":" | ","alterations":" GLI1 overexpression","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GLI1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZSP1602"],"overall_status":"Unknown status","enrollment":" Enrollment 65","initiation":"Initiation: 01/25/2019","start_date":" 01/25/2019","primary_txt":" Primary completion: 07/31/2021","primary_completion_date":" 07/31/2021","study_txt":" Completion: 07/31/2021","study_completion_date":" 07/31/2021","last_update_posted":"2020-07-22"},{"id":"96842ea0-1da9-4149-ba34-ced2a2b292bb","acronym":"BRIGHT AML","url":"https://clinicaltrials.gov/study/NCT01546038","created_at":"2024-01-07T00:16:58.018Z","updated_at":"2024-07-02T16:36:49.330Z","phase":"Phase 1b/2","brief_title":"A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT01546038 - BRIGHT AML","lead_sponsor":"Pfizer","biomarkers":" RUNX1","pipe":"","alterations":" ","tags":["RUNX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • daunorubicin • Daurismo (glasdegib)"],"overall_status":"Completed","enrollment":" Enrollment 255","initiation":"Initiation: 06/27/2012","start_date":" 06/27/2012","primary_txt":" Primary completion: 01/03/2017","primary_completion_date":" 01/03/2017","study_txt":" Completion: 03/04/2019","study_completion_date":" 03/04/2019","last_update_posted":"2020-03-03"},{"id":"fb5922c2-88de-441b-8c08-5a08e614bed9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01919398","created_at":"2021-01-18T08:39:32.118Z","updated_at":"2024-07-02T16:36:55.807Z","phase":"Phase 1","brief_title":"A Study of LY2940680 in Japanese Participants With Advanced Cancers","source_id_and_acronym":"NCT01919398","lead_sponsor":"Eli Lilly and Company","biomarkers":" GLI1","pipe":"","alterations":" ","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e taladegib (ENV 101)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/01/2013","start_date":" 08/01/2013","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 06/28/2017","study_completion_date":" 06/28/2017","last_update_posted":"2019-09-11"},{"id":"eb9d7533-26cc-4fc3-b452-3eeed4ed6f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT02828111","created_at":"2021-01-18T13:51:59.563Z","updated_at":"2024-07-02T16:37:04.121Z","phase":"Phase 2","brief_title":"Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas","source_id_and_acronym":"NCT02828111","lead_sponsor":"PellePharm, Inc.","biomarkers":" GLI1","pipe":"","alterations":" ","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patidegib topical (SGT-610)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 11/11/2016","start_date":" 11/11/2016","primary_txt":" Primary completion: 11/09/2017","primary_completion_date":" 11/09/2017","study_txt":" Completion: 11/09/2017","study_completion_date":" 11/09/2017","last_update_posted":"2019-01-08"},{"id":"00c91ab4-92f1-495c-8d93-32c76994ed4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00980343","created_at":"2021-01-18T03:49:30.966Z","updated_at":"2024-07-02T16:37:18.798Z","phase":"Phase 2","brief_title":"GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery","source_id_and_acronym":"NCT00980343","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ","pipe":"","alterations":" ","tags":["Erivedge (vismodegib)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 06/01/2012","study_completion_date":" 06/01/2012","last_update_posted":"2017-08-16"}]